![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 2
Zeitschriftenartikel
Wolff, Andreas W.; Bidner, Helen; Remane, Yvonne; Zimmer, Janine; Aarsland, Dag; Rascol, Olivier; Wyse, Richard K.; Hapfelmeier, Alexander und Lingor, Paul
(2024):
Protocol for a randomized, placebo-controlled, double-blind phase IIa study of the safety, tolerability, and symptomatic efficacy of the ROCK-inhibitor Fasudil in patients with Parkinson's disease (ROCK-PD).
In: Frontiers in Aging Neuroscience, Bd. 16, 1308577
[PDF, 566kB]
Koch, Jan C; Leha, Andreas; Bidner, Helen; Cordts, Isabell; Dorst, Johannes; Günther, René; Zeller, Daniel; Braun, Nathalie; Metelmann, Moritz; Corcia, Philippe; Cruz, Elisa De La; Weydt, Patrick; Meyer, Thomas; Großkreutz, Julian; Soriani, Marie-Hélène; Attarian, Shahram; Weishaupt, Jochen H; Weyen, Ute; Kuttler, Josua; Zurek, Gabriela; Rogers, Mary-Louise; Feneberg, Emily; Deschauer, Marcus 
ORCID: https://orcid.org/0000-0001-6116-6790; Neuwirth, Christoph; Wuu, Joanne; Ludolph, Albert C; Schmidt, Jens; Remane, Yvonne; Camu, William; Friede, Tim; Benatar, Michael; Weber, Markus und Lingor, Paul
(2024):
Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS). A phase 2, randomised, double-blind, placebo-controlled trial.
In: Lancet Neurology, Bd. 23, Nr. 11: S. 1133-1146
[PDF, 849kB]
ORCID: https://orcid.org/0000-0001-6116-6790; Neuwirth, Christoph; Wuu, Joanne; Ludolph, Albert C; Schmidt, Jens; Remane, Yvonne; Camu, William; Friede, Tim; Benatar, Michael; Weber, Markus und Lingor, Paul
(2024):
Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS). A phase 2, randomised, double-blind, placebo-controlled trial.
In: Lancet Neurology, Bd. 23, Nr. 11: S. 1133-1146
[PDF, 849kB]